- ￥191 - 2788
- MedChemExpress(MCE)
- 美国
- HY-16585
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AI 赋能培养基定制开发：CHO 培养基是如何实现产量提升Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
SB2343
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1246560-33-7
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥312.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥191.0 |
| 规格： | 5 mg | 产品价格： | ￥400.0 |
| 规格： | 10 mg | 产品价格： | ￥700.0 |
| 规格： | 25 mg | 产品价格： | ￥1250.0 |
| 规格： | 50 mg | 产品价格： | ￥1863.0 |
| 规格： | 100 mg | 产品价格： | ￥2788.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
VS-5584
CAS No. : 1246560-33-7
MCE 国际站：VS-5584
产品活性：VS-5584 是一种 pan-PI3K/mTOR 激酶抑制剂，抑制 PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ 和 mTOR，IC50 分别为 16 nM, 68 nM, 42 nM, 25 nM 和 37 nM。VS-5584 同时阻断 mTORC2 和 mTORC1。
研究领域：PI3K/Akt/mTOR
In Vitro: VS-5584 is an ATP-competitive inhibitor which selectively inhibits PI3K/mTOR signaling with equivalent low nanomolar potency against all human Class I PI3K isoforms and mTOR kinase. VS-5584 (0.001, 0.01, 0.1,1,10 and 100 μM) preferentially inhibits cancer stem cells in HMLE breast cancer cells while Paclitaxel increases the percentage of cancer stem cells. VS-5584 (0.1, 1, 10, 100 and 1000 nM) reduces the number of Aldefluor-positive cancer stem cells while Paclitaxel increases the percentage of cancer stem cells. VS-5584 (10, 30, 100, 300 nM) reduces the percentage of cancer stem cells (side population) in a Hoechst dye exclusion assay. VS-5584 is a potent inhibitor of mTOR (IC50=37 nM) as well as class I PI3K isoforms (IC50: PI3Kα=16 nM; PI3Kβ=68 nM; PI3Kγ=25 nM; PI3Kδ=42 nM). All other evaluated kinases show negligible binding when tested up to 10 μM VS-5584.
In Vivo: Nude mice bearing MDA-MB-231 human breast cancer tumors are treated for 5 days with once daily oral VS-5584 (25 mg/kg). Oral treatment of tumor bearing mice with VS-5584 reduces cancer atem cells analyzed from extracted tumors. Mice are implanted with tumor fragments from a docetaxel-resistant patient-derived triple negative breast cancer. Mice are treated with VS-5584 (20 mg/kg, po, qd) or Docetaxel (20 mg/kg, i.v.). Oral VS-5584 induces tumor regression in a Docetaxel-resistant patient-derived breast cancer model. A single oral dose of VS-5584 is rapidly absorbed with a tmax of 0.9 hours and an elimination half-life of 10 hours. To determine the pharmacokinetic and pharmacodynamic relationship in tumors, PC3-tumor–bearing mice are treated with a single dose of VS-5584 and plasma and tumors are harvested after 6 hours and analyzed for concentrations of VS-5584 and effects on target efficacy biomarkers. Plasma levels of VS-5584 increase dose-dependently. For evaluation of efficacy in a Rapamycin-sensitive PC3 engraftment model, tumor-bearing mice are treated with VS-5584 for 28 days in comparison with the rapalog Everolimus. VS-5584 is well tolerated at both doses tested (11 and 25 mg/kg) with minimal weight loss (mean 4.7% on day 27). Treatment with VS-5584 leads to significant tumor growth inhibition (TGI) of 79% and 113% for 11 and 25 mg/kg, respectively.
相关产品：Clinical Compound Library Plus | Bioactive Compound Library Plus | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Antioxidant Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Glutamine Metabolism Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Angiogenesis-Related Compound Library | Lipid Metabolism Compound Library | Glucose Metabolism Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Rapamycin | 3-Methyladenine | LY294002 | Alpelisib | Quercetin | Everolimus | MHY1485 | Wortmannin | Torin 1 | 740 Y-P | AZD-8055 | Idelalisib | Buparlisib | Inavolisib | Dactolisib | Sapanisertib | Eganelisib | Pictilisib | Copanlisib | SAR405 | JR-AB2-011 | 3BDO | Duvelisib | Salidroside | Torin 2 | Temsirolimus | Recilisib | YM-201636 | L-Leucine | Torkinib
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Sucrose Fractionation of Castor Bean
Materials Castor beans Gradient former Sucrose solutions in 0.01 M EDTA, pH 7.5 33%, 44%, 50%, 57%, 60% (w/v) Grinding Medium 0.4 M sucrose 0.165 M Tris-HCl buffer, pH 7.5 0.01 M KCl
*** Make sure the agar equilibrates to 55 C to 60 C before starting the assay; otherwise it will kill the cells. 3. Distribute several paper disks (Difco, #1599-33-6) into a sterile petri dish, and spot either 5 or 15 of synthetic alpha-factor (1 - 5 mg
: increase in stromal cells from mild to severe dysplasia to invasive carcinoma, Hum Path 2002;33:806-8 Endometriosis: helpful in identifying areas of endometriosis if sparse glandular tissue Follicular lymphoma: to confirm diagnosis
技术资料暂无技术资料 索取技术资料
